Bio-Techne Corporation
TECH
$60.24
$1.773.02%
| Weiss Ratings | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C+ | |||
| Rating Factors | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Weak | |||
| Growth Index | Fair | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.15 | |||
| Price History | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.56% | |||
| 30-Day Total Return | -19.16% | |||
| 60-Day Total Return | -21.49% | |||
| 90-Day Total Return | -14.66% | |||
| Year to Date Total Return | -15.63% | |||
| 1-Year Total Return | -18.38% | |||
| 2-Year Total Return | -15.39% | |||
| 3-Year Total Return | -37.78% | |||
| 5-Year Total Return | 47.63% | |||
| 52-Week High % Change | -31.67% | |||
| 52-Week Low % Change | 0.46% | |||
| Price | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $85.57 | |||
| 52-Week Low Price | $58.20 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | May 15, 2024 | |||
| Valuation | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 9.24B | |||
| Enterprise Value | 9.46B | |||
| Price/Earnings (TTM) | 58.65 | |||
| Earnings Per Share (TTM) | 1.00 | |||
| Earnings Per Share Growth | -27.25% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 7.85 | |||
| Price/Book (Q) | 4.44 | |||
| Enterprise Value/Revenue (TTM) | 7.91 | |||
| Price | $60.24 | |||
| Enterprise Value/EBITDA (TTM) | 26.53 | |||
| Enterprise Value/EBIT | 38.46 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 160.63M | |||
| Dividend Yield | 0.55% | |||
| Div. Per Share (Most Recent) | $0.08 | |||
| Dividend Per Share (TTM) | $0.32 | |||
| Payout Ratio (TTM) | 32.02% | |||
| Dividend Per Share (Most Recent) | $0.08 | |||
| Company Info | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 612 379 8854 | |||
| Address | 614 McKinley Place N.E. Minneapolis, MN 55413 | |||
| Website | www.bio-techne.com | |||
| Country | United States | |||
| Year Founded | 1976 | |||
| Profitability | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 20.56% | |||
| Profit Margin | 13.22% | |||
| Management Effectiveness | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.69% | |||
| Return on Equity | 7.82% | |||
| Income Statement | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.20B | |||
| Total Revenue (TTM) | 1.20B | |||
| Revenue Per Share | $7.45 | |||
| Gross Profit (TTM) | 792.00M | |||
| EBITDA (TTM) | 356.59M | |||
| EBIT (TTM) | 246.00M | |||
| Net Income (TTM) | 158.14M | |||
| Net Income Avl. to Common (TTM) | 158.14M | |||
| Total Revenue Growth (Q YOY) | 8.96% | |||
| Earnings Growth (Q YOY) | 27.03% | |||
| EPS Diluted (TTM) | 1.00 | |||
| EPS Diluted Growth (Q YOY) | 29.41% | |||
| Balance Sheet | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 177.55M | |||
| Cash Per Share (Q) | $1.11 | |||
| Total Current Assets (Q) | 634.64M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.08B | |||
| Current Ratio (Q) | 3.936 | |||
| Book Value Per Share (Q) | $13.16 | |||
| Total Assets (Q) | 2.67B | |||
| Total Current Liabilities (Q) | 161.26M | |||
| Total Debt (Q) | 395.13M | |||
| Total Liabilities (Q) | 591.93M | |||
| Total Common Equity (Q) | 2.08B | |||
| Cash Flow | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -51.97M | |||
| Cash from Financing (TTM) | -207.92M | |||
| Net Change in Cash (TTM) | 47.42M | |||
| Levered Free Cash Flow (TTM) | 250.19M | |||
| Cash from Operations (TTM) | 304.72M | |||
